Related Experiment Video
Updated: Aug 9, 2026

14:26
Purification of Extracellular Trypanosomes, Including African, from Blood by Anion-Exchangers Diethylaminoethyl-cellulose Columns
Published on: April 6, 2019
10.7K
Metabolic Control Analysis for Drug Target Prioritization in Trypanosomatids
Zabdi González-Chávez1, Citlali Vázquez1, Rafael Moreno-Sánchez1
1Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico.
Methods in Molecular Biology (Clifton, N.J.)
|March 30, 2020
Summary
Metabolic control analysis (MCA) identifies essential enzymes in parasite metabolic pathways. This method, using flux control coefficients, prioritizes drug targets beyond simple gene knockout studies.
Area of Science:
- Parasitology
- Biochemistry
- Systems Biology
Background:
- Enzyme essentiality via gene knockout/knockdown is insufficient for prioritizing therapeutic targets in trypanosomatids.
- Most analyzed enzymes in these parasites are essential, necessitating additional criteria for drug target selection.
Purpose of the Study:
- To introduce Metabolic Control Analysis (MCA) as a method for prioritizing enzymes as drug targets in trypanosomatid metabolic pathways.
- To explain how MCA quantifies enzyme control over pathway flux using flux control coefficients ([Formula: see text]).
Main Methods:
- Review of three approaches to determine flux control coefficients: in vitro pathway reconstitution, manipulation of enzyme activities, and in silico kinetic modeling.
- Emphasis on the need for accurate experimental data (enzyme activities, metabolite concentrations, pathway fluxes) for MCA.
- Illustration of MCA methodology using trypanothione metabolism in *Trypanosoma cruzi*.
Main Results:
- MCA establishes the distribution of metabolic control, identifying key flux-controlling steps within a pathway.
- This allows for a metabolic-based ranking of pathway enzymes as potential drug targets.
Conclusions:
- Metabolic Control Analysis provides a robust framework for prioritizing drug targets in trypanosomatids by quantifying enzyme control.
- The described MCA strategy and protocols are applicable to any metabolic pathway in these parasites.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

